Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing.

Menlyadiev, Marlen; Suhandynata, Raymond T; Lund, Kyle; Kelner, Michael J; Fitzgerald, Robert L

Menlyadiev, Marlen; Suhandynata, Raymond T; Lund, Kyle; Kelner, Michael J; Fitzgerald, Robert L.

Afiliación

Menlyadiev M; Department of Pathology, Center for Advanced Laboratory Medicine, University of California, San Diego Health Systems, San Diego, CA, United States.
Suhandynata RT; Department of Pathology, Center for Advanced Laboratory Medicine, University of California, San Diego Health Systems, San Diego, CA, United States.
Lund K; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, United States.
Kelner MJ; Department of Pathology, Center for Advanced Laboratory Medicine, University of California, San Diego Health Systems, San Diego, CA, United States.
Fitzgerald RL; Department of Pathology, Center for Advanced Laboratory Medicine, University of California, San Diego Health Systems, San Diego, CA, United States.

J Mass Spectrom Adv Clin Lab ; 28: 105-113, 2023 Apr.

Article en En | MEDLINE | ID: mdl-37025609

Palabras clave

Clinical sensitivity; FEN2; Fentanyl; Immunoassay; Mass spectrometry; Norfentanyl

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Mass Spectrom Adv Clin Lab Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos